pembrolizumab,nivolumab,ipilimumab
merck,bms
['/ipi', 'sarcoma', 'rcc,(-irccs),(-srcc),(-urcc)', 'nivo', 'kn-564']
#esmo22 presidential symposium - adjuvant nivo/ipi in #rcc by :
- 15% pt2a g3/4, pt2b
- 5% sarcomatoid (pdl1 status pending)
- placebo arm 24-mos dfs rate 74% (note 67% in kn-564)
- 1 in 3 d/c due to drug tox 
Medical Oncologist, @HamHealthSci | Assistant Professor, @McMasterU | Former Fellow, @DanaFarber | Academic focus: genitourinary & rare cancers | Views my own.